CoChat

From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases

Open access
Cassano, Tommaso, Villani, Rosanna, Pace, Lorenzo, Carbone, Antonio, Bukke, Vidyasagar Naik, Orkisz, Stanislaw, Avolio, Carlo, Serviddio, Gaetano · 2020 · Frontiers in Pharmacology
Cited by 144

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Cannabis sativa, commonly known as marijuana, represents a reservoir of compounds exerting beneficial properties. Besides Δ9-tetrahydrocannabinol that is responsible for the psychotropic effect associated with Cannabis consumption, cannabidiol (CBD) is the most abundant nonpsychoactive phytocannabinoid and may represent a prototype for anti-inflammatory drug development for human pathologies where is involved the activation of immune system and oxidative stress (OS), as a contributor to their aetiology and progression. To this regard, OS has been implicated in the progression of a number of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD). These diseases are characterized by extensive oxidative damage to different biological substrates that can lead to cell death by a variety of different mechanisms. Most cases of neurodegenerative diseases have a complex aetiology with numerous genetic and environmental factors contributing to progression; therefore, biomarker and treatment strategies may require simultaneous targeting of multiple components, including some specific to disease stage, in order to assess and modulate neurodegeneration. In this context, CBD, which interacts with the endocannabinoid system, but has also cannabinoid receptor-independent mechanism, might be a good candidate as a prototype for anti-oxidant drug development. The wide range of targets of CBD emphasizes its potential as a multimodal drug for the major neurodegenerative disorders, such as PD and AD. The present review summarizes the multiple biochemical and molecular mechanisms that have been associated with the therapeutic effects of CBD that may have a considerable impact on the progression of the major neurodegenerative disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2020.00124

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

Metadata

Authors
Cassano, T., Villani, R., Pace, L., Carbone, A., Bukke, V. N., Orkisz, S., Avolio, C., & Serviddio, G.
Venue
Frontiers in Pharmacology
Published
2020-03-06
Volume
11
Pages
124-124
ISSN
1663-9812 (ISSN-L)
OpenAlex
W3009563806
Cited by
144
References
28
FWCI
11.20
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.